Patient-Owned Health Data Model Reduces Clinical Trial Recruitment Redundancy
患者主導の健康データモデルが治験の重複課題を解決
Summary
The article argues that the patient-owned health data model addresses the inefficiency of current clinical trials, which require patients to repeatedly re-consent and redundantly request records across separate studies. This model proposes transforming research activities from episodic interactions into ongoing infrastructure.
Details
The traditional model treats each protocol as a discrete relationship, leading to measurable inefficiency—such as redundant records requests and repeat consent conversations—when the same patient population is needed for multiple studies (e.g., observational work, RWE, label extensions). The patient-owned model proposes a single, persistent consented relationship across these activities. Interoperability is key to this scale-up, with ONC data showing that 69% of US hospitals adopted FHIR-based applications by 2024. This allows patients to aggregate their records across provider, pharmacy, and payer systems into a single view for research. Furthermore, regulatory bodies are adapting: the FDA accepts Patient-Reported Outcome (PRO) data in oncology trials, and the EMA is developing guidance on integrating patient experience data and RWD, signaling a shift toward continuous, longitudinal data assets.
Original content copyright by respective publishers